Clinical Trial With Aconite Pain Oil in Oncology Patients Under Chemotherapy to Prevent CIPN Grade-II, to Reduce Symptoms and to Improve the Quality of Life of Patients With CIPN

Chemotherapy-induced Polyneuropathy Clinical Trial

Official title: Clinical Trial With Aconite Pain Oil in Oncology Patients Under Chemotherapy to Prevent Grade-II Chemotherapy-induced Polyneuropathy (CIPN), to Reduce Symptoms Typical of CIPN, and to Improve the Quality of Life of Patients With CIPN

Status Recruiting

Clinical Trial Summary

The clinical trial is planned as a prospective, multicentre, blinded, randomised, placebo-controlled, national clinical trial in Germany. The clinical trial is designed for testing the prophylactic and therapeutic effects of Aconite pain oil as compared to placebo in oncological patients receiving neurotoxic chemotherapy with taxanes and/or platinum derivatives.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chemotherapy-induced Polyneuropathy
• Polyneuropathies

• NCT number: NCT06186479
• Study type: Interventional
• Source: WALA Heilmittel GmbH
• Contact: Florian Stintzing, Prof. Dr.
• Email: klin-pruef-klifo@wala.de
• Status: Recruiting
• Phase: Phase 3
• Start date: March 13, 2024
• Completion date: July 1, 2027